These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34694325)

  • 21. [Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].
    Dal-Ré R
    Rev Neurol; 2021 Oct; 73(8):296-297. PubMed ID: 34617583
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Middle Ground for Accelerated Drug Approval-Lessons From Aducanumab.
    Emanuel EJ
    JAMA; 2021 Oct; 326(14):1367-1368. PubMed ID: 34554184
    [No Abstract]   [Full Text] [Related]  

  • 23. Knowledge and Attitudes Concerning Aducanumab Among Older Americans After FDA Approval for Treatment of Alzheimer Disease.
    Zissimopoulos J; Jacobson M; Chen Y; Borson S
    JAMA Netw Open; 2022 Feb; 5(2):e2148355. PubMed ID: 35157058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.
    Lythgoe MP; Prasad V
    Eur J Cancer; 2021 Nov; 157():68-70. PubMed ID: 34487987
    [No Abstract]   [Full Text] [Related]  

  • 25. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?
    Planche V; Villain N
    JAMA Neurol; 2021 Nov; 78(11):1307-1308. PubMed ID: 34515750
    [No Abstract]   [Full Text] [Related]  

  • 26. FDA approves Alzheimer's drug lecanemab amid safety concerns.
    Reardon S
    Nature; 2023 Jan; 613(7943):227-228. PubMed ID: 36627422
    [No Abstract]   [Full Text] [Related]  

  • 27. Of education and public policy: Aducanumab.
    Lundebjerg NE; Hollmann PA; Supiano MA
    J Am Geriatr Soc; 2022 Jan; 70(1):81-84. PubMed ID: 34674219
    [No Abstract]   [Full Text] [Related]  

  • 28. Editorial: Consequences of the FDA Decision on Aducanumab for Patient Care and Research.
    Doody R
    J Prev Alzheimers Dis; 2021; 8(4):393-395. PubMed ID: 34585210
    [No Abstract]   [Full Text] [Related]  

  • 29. Controversial Alzheimer's drug approval could affect other diseases.
    Mullard A
    Nature; 2021 Jul; 595(7866):162-163. PubMed ID: 34193994
    [No Abstract]   [Full Text] [Related]  

  • 30. Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.
    Alexander GC; Emerson S; Kesselheim AS
    JAMA; 2021 May; 325(17):1717-1718. PubMed ID: 33783469
    [No Abstract]   [Full Text] [Related]  

  • 31. Accelerated Approval of Aducanumab: Where Do We Stand Now?
    Barenholtz Levy H
    Ann Pharmacother; 2022 Jun; 56(6):736-739. PubMed ID: 34595939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Not Available].
    Watt JA; Marple R; Hemmelgarn B; Straus SE
    CMAJ; 2021 Nov; 193(43):E1680-E1682. PubMed ID: 34725122
    [No Abstract]   [Full Text] [Related]  

  • 33. What to Know About the Alzheimer Drug Aducanumab (Aduhelm).
    Woloshin S; Kesselheim AS
    JAMA Intern Med; 2022 Aug; 182(8):892. PubMed ID: 35666531
    [No Abstract]   [Full Text] [Related]  

  • 34. Aducanumab and the FDA - where are we now?
    Fillit H; Green A
    Nat Rev Neurol; 2021 Mar; 17(3):129-130. PubMed ID: 33442064
    [No Abstract]   [Full Text] [Related]  

  • 35. "Real-world" eligibility for aducanumab depends on clinical setting and patients' journey.
    Padovani A; Caratozzolo S; Rozzini L; Pilotto A; Benussi A; Tedeschi G
    J Am Geriatr Soc; 2022 Feb; 70(2):626-628. PubMed ID: 34750815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer's drug approval gets a mixed reception.
    Couzin-Frankel J
    Science; 2023 Jan; 379(6628):126-127. PubMed ID: 36634171
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Landmark Alzheimer's drug approval confounds research community.
    Mullard A
    Nature; 2021 Jun; 594(7863):309-310. PubMed ID: 34103732
    [No Abstract]   [Full Text] [Related]  

  • 38. The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1.
    de la Torre JC; Gonzalez-Lima F
    J Alzheimers Dis; 2021; 82(3):881-882. PubMed ID: 34250943
    [No Abstract]   [Full Text] [Related]  

  • 39. Seamless Oncology-Drug Development.
    Prowell TM; Theoret MR; Pazdur R
    N Engl J Med; 2016 May; 374(21):2001-3. PubMed ID: 27074059
    [No Abstract]   [Full Text] [Related]  

  • 40. Can we learn lessons from the FDA's approval of aducanumab?
    Liu KY; Howard R
    Nat Rev Neurol; 2021 Nov; 17(11):715-722. PubMed ID: 34535787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.